title: Overexpression of miR-210 is Associated with Poor Prognosis of Acute Myeloid Leukemia.
abstract: BACKGROUND
  MicroRNAs play important roles in regulation of the initiation and progression of AML. MiR-210 is closely related with cancer development; however, whether miR-210 expression level correlates with clinical correlation in AML is unknown. Thus, the aim of this study was to investigate the potential relationship between miR-210 expression and AML prognosis.
  
  
  METHODS
  Real-time quantitative PCR was carried out to examine the expression level of miR-210 in bone marrow and serum obtained from AML patients and healthy controls. Then the correlation between miR-210 expression and a variety of important clinical parameters (such as overall survival, relapse-free survival, and prognostic value) were further studied.
  
  
  RESULTS
  The expression level of miR-210 was significantly higher in the bone marrow and serum of AML patients than that of healthy controls (p<0.001). Moreover, miR-210 expression was associated with various AML clinicopathological parameters, including FAB classification and cytogenetics. The serum miR-210 expression level was reduced significantly when the patients achieved complete remission (p=0.02). The high miR-210 expression group had both poorer relapse-free survival (p=0.015) and worse overall survival (p=0.008). In the multivariate analysis model, miR-210 was identified as an independent prognostic marker.
  
  
  CONCLUSIONS
  MiR-210 up-regulation was associated with poor prognosis in AML and it might be useful as a marker for predicting the clinical outcome of AML patients.
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
authors.forename: Xiaoqiong
authors.initials: X
authors.lastname: Tang
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
authors.forename: Liping
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
authors.forename: Xinyu
authors.initials: X
authors.lastname: Yan
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
authors.forename: Yuanjie
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
authors.forename: Yuanlin
authors.initials: Y
authors.lastname: Xiong
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
authors.forename: Xiaohui
authors.initials: X
authors.lastname: Zhou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000378:metabolism; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000235:genetics*; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D060888:Real-Time Polymerase Chain Reaction; D012008:Recurrence; D012074:Remission Induction; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C543800:MIRN210 microRNA, human; D035683:MicroRNAs